Spero Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SPRO | VERU | ACXP | LXRX | NIKI | 1952.HK | |
|---|---|---|---|---|---|---|
| Market cap | 62.31M | 37.51M | 5.64M | 658.53M | 5.27M | 9.83B |
| P/E (TTM) | 7.6 | — | — | — | — | — |
| Forward P/E | -1.0 | -2.2 | -0.6 | -7.8 | — | 20.4 |
| Price/book | 1.4 | 1.3 | 0.6 | 3.8 | 0.1 | 1.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −55.23% | −15.63% | −80.19% | +3.50% | −87.43% | −44.53% |
| Today | +2.88% | +1.85% | +0.98% | +1.37% | −3.98% | +5.06% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All SPRO news ›Spero Therapeutics (NASDAQ:SPRO) Downgraded by Wall Street Zen to Sell
Posted by Tristan Rich on Nov 1st, 2026 Wall Street Zen lowered shares of Spero Therapeutics (NASDAQ:SPRO – Free Report) from a hold rating to a sell rating in a research report report published on Saturday morning,Wall Street Zen reports.…
Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock Has Average Target Price of $6.00
Posted by Defense World Staff on Oct 31st, 2026 Get Our Latest Stock Report on SPRO SPRO opened at $1.06 on Wednesday. The firm has a market capitalization of $61.73 million, a P/E ratio of 10.09 and a beta of 1.50. Spero Therapeutics has…
Spica Therapeutics appoints Jeff Abbey as CEO
Find pharmaceutical jobs, news, career advice and articles on PMLive, the leading resource for the pharmaceutical and healthcare industry. Spica Therapeutics appoints Jeff Abbey as CEO Spica Therapeutics has appointed Jeff Abbey as Chief…
Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Research Reveals Strong 5.5% CAGR Outlook Through 2030
The sphingosine 1 phosphate receptor S1PR modulator drugs market is witnessing robust expansion as advancements in immunotherapy and neurology continue to evolve With growing prevalence of autoimmune disorders and innovations in oral…
Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
The Manila Times Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopha
Complicated Urinary Tract Infections Market Set for Expansion by 2036, Supported by Recent Drug Approvals Including GSK/Spero Therapeutics’ UTEBZI and Wockhardt’s ZAYNICH and Emerging Therapies | DelveInsight
New York, USA, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Complicated Urinary Tract Infections Market Set for Expansion by 2036, Supported by Recent Drug Approvals Including GSK/Spero Therapeutics’ UTEBZI and Wockhardt’s ZAYNICH and Emerging…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- businessupturn.com1
- defenseworld.net1
- globenewswire.com1
- manilatimes.net1
- openpr.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.